Article Sidebar

pdf
Date Published: 04/11/2025
Abstract Views: 190
Views pdf: 78
DOI: https://doi.org/10.51298/vmj.v555i2.16002
Issue
Vol. 555 No. 2 (2025)
Section
Các bài báo
How to Cite
Lê, T. Y., & Nguyễn, T. D. D. (2025). THE EFFICACY OF IRINOTECAN MONOTHERAPY AS SECOND-LINE TREATMENT IN PATIENTS WITH ADVANCED GASTRIC CANCER. Vietnam Medical Journal, 555(2). https://doi.org/10.51298/vmj.v555i2.16002

THE EFFICACY OF IRINOTECAN MONOTHERAPY AS SECOND-LINE TREATMENT IN PATIENTS WITH ADVANCED GASTRIC CANCER

Thị Yến Lê, Thị Dương Dương Nguyễn

Main Article Content

Abstract

Objectives: To evaluate the efficacy of trastuzumab combined with chemotherapy treatment in patients with recurrent/metastatic gastric cancer with HER2/neu positive. Patients and methods: Descriptive, retrospective, longitudinal case study of 55 patients with recurrent/metastatic gastric cancer treated with trastuzumab combined with chemotherapy from 01/2023 to 06/2025 at Vietnam’s National Cancer Hospital. Results: The mean age was 59,4 ± 11,1 (34-80); the male/female ratio was 1,5/1. The overall response rate (ORR) was 49,1%, the DCR was 81,8%. The mean progression-free survival (PFS) was 10,3 ± 1,43 months, and the median progression-free survival was 6,4 months. Conclusion: In patients with recurrent/metastatic gastric cancer with HER2/neu positive, trastuzumab plus chemotherapy is a reasonable treatment option.

Article Details

Keywords

recurrent/metastatic gastric cancer, trastuzumab, HER2/neu.

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May‑Jun;74(3):229‑263.
2. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389-1396.
3. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet Lond Engl. 2019;393(10184):1948-1957.
4. Stomach (Gastric) Cancer Survival Rates. Accessed March 5, 2025. https://www.cancer.org/ cancer/types/stomach-cancer/detection-diagnosis-staging/survival-rates.html.
5. Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World J Gastroenterol. 2016;22(19):4619-4625.
6. Jørgensen JT, Hersom M. HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer. 2012;3:137-144.
7. Bang YJ, Cutsem EV, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 2010;376(9742):687-697.
8. Chan Thi Thuy Linh, Pham Tuan Anh, Le Van Quang. Kết quả điều trị trastuzumab kết hợp hóa trị UTDD giai đoạn muộn. Luận văn thạc sĩ y học, Trường đại học Y Hà Nội; 2023.
9. Quách Thị Dung, Vũ Hồng Thăng. Đánh giá kết quả điều trị TS-1 và oxaliplatin trong UTDD giai đoạn muộn tại bệnh viện K. Luận văn thạc sĩ y học, Trường đại học Y Hà Nội; 2022.
10. Nguyễn Văn Hùng, Vũ Hồng Thăng. Đánh giá kết quả điều trị duy trì UTDD tái phát di căn bằng phác đồ FOLFIRI. Luận văn thạc sĩ y học, Trường đại học Y Hà Nội; 2018.